These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25357073)

  • 21. Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.
    Burger CF; Schlesinger JJ
    Ann Pharmacother; 2014 Feb; 48(2):286-91. PubMed ID: 24259642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Argatroban for anticoagulation during cardiopulmonary bypass in an infant.
    Dyke PC; Russo P; Mureebe L; Russo J; Tobias JD
    Paediatr Anaesth; 2005 Apr; 15(4):328-33. PubMed ID: 15787926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete salvage of impending free flap failure in heparin induced thrombocytopenia by emergent institution of therapy with argatroban.
    Schleich AR; Oswald TM; Lineaweaver WC
    J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):1263-4. PubMed ID: 18632316
    [No Abstract]   [Full Text] [Related]  

  • 24. CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
    Greinacher A
    N Engl J Med; 2015 Jul; 373(3):252-61. PubMed ID: 26176382
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
    Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L
    Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anesthesia for a hemodialysis patient with HIT undergoing CABG using argatroban].
    Goto S; Hiramori T; Kuroiwa K; Mochizuki N; Takano T; Nishizawa M
    Masui; 2012 Apr; 61(4):397-9. PubMed ID: 22590944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.
    Matsuo T; Koide M; Kario K
    Artif Organs; 1997 Sep; 21(9):1035-8. PubMed ID: 9288875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Argatroban approved for heparin-induced thrombocytopenia.
    Miller JL
    Am J Health Syst Pharm; 2000 Sep; 57(18):1650. PubMed ID: 11006790
    [No Abstract]   [Full Text] [Related]  

  • 29. Challenging Argatroban Management of a Child on Extracorporeal Support and Subsequent Heart Transplant.
    Latham GJ; Jefferis Kirk C; Falconer A; Dickey R; Albers EL; McMullan DM
    Semin Cardiothorac Vasc Anesth; 2016 Jun; 20(2):168-74. PubMed ID: 26721808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Argatroban therapy for heparin-induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency.
    Tanimura K; Ebina Y; Sonoyama A; Morita H; Miyata S; Yamada H
    J Obstet Gynaecol Res; 2012 Apr; 38(4):749-52. PubMed ID: 22380425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor.
    Matsuo T; Kario K; Chikahira Y; Nakao K; Yamada T
    Br J Haematol; 1992 Nov; 82(3):627-9. PubMed ID: 1486048
    [No Abstract]   [Full Text] [Related]  

  • 32. Argatroban to achieve therapeutic anticoagulation in two patients with acute thrombosis and heparin resistance.
    Mindlina I; Nelmes E; Sharp M; Butler A; Gudgin E; Thomas W
    Blood Coagul Fibrinolysis; 2019 Dec; 30(8):426-428. PubMed ID: 31567267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
    Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient.
    Edwards JT; Hamby JK; Worrall NK
    Ann Thorac Surg; 2003 May; 75(5):1622-4. PubMed ID: 12735590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
    Schumacher WA; Heran CL; Steinbacher TE
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
    Schneider J
    Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for heparin-induced thrombocytopenia.
    Greinacher A
    Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S12-8. PubMed ID: 14593978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of argatroban.
    Jeske WP; Fareed J; Hoppensteadt DA; Lewis B; Walenga JM
    Expert Rev Hematol; 2010 Oct; 3(5):527-39. PubMed ID: 21083469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
    Dee B; Lombardi Thomas L; Gulbis A
    Am J Health Syst Pharm; 2014 May; 71(9):711-6. PubMed ID: 24733133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
    Valji K; Arun K; Bookstein JJ
    J Vasc Interv Radiol; 1995; 6(1):91-5. PubMed ID: 7703589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.